

1. Lennard L, Cartwright CS, Wade R, et al. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. *Br J Clin Pharmacol* 2013;76(1):125–136.
2. Haber DA, Settleman J. Cancer: drivers and passengers. *Nature* 2007;446(7132):145–146.
3. Hayashi T, Sudo J. Relieving effect of saline on cephaloridine nephrotoxicity in rats. *Chem Pharm Bull (Tokyo)* 1989;37(3):785–790.
4. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. *Science* 1984;224(4653):1121–1124.
5. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. *N Engl J Med* 1985;313(18):1111–1116.
6. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. *Oncologist* 2003;8(3):278–292.
7. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. *Blood* 1990;76(8):1449–1463.
8. Lee JA, Lupski JR. Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders. *Neuron* 2006;52(1):103–121.
9. Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, et al. Germline copy number variation and cancer risk. *Curr Opin Genet Dev* 2010;20(3):282–289.
10. Shlien A, Malkin D. Copy number variations and cancer. *Genome Med* 2009;1(6):62.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350(21):2129–2139.
12. Paez JC, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304(5676):1497–1500.
13. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res* 2011;39(Database issue):D945–950.
14. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. *J Clin Oncol* 2013;31(15):1825–1833.
15. Newman B, Mu H, Butler LM, et al. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. *JAMA* 1998;279(12):915–921.
16. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998;62(3):676–689.
17. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72(5):1117–1130.
18. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. *J Clin Oncol* 2006;24(6):863–871.
19. Bachner P, Hamlin W. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988—Part II. *Clin Lab Med* 1993;13(4):987–994.
20. Halling KC, Schrijver I, Persons DL. Test verification and validation for molecular diagnostic assays. *Arch Pathol Lab Med* 2012;136(1):11–13.
21. Jennings L, Van Deerlin VM, Gulley ML, College of American Pathologists Molecular Pathology Resource C. Recommended principles and practices for validating clinical molecular pathology tests. *Arch Pathol Lab Med* 2009;133(5):743–755.
22. Jennings LJ, Smith FA, Halling KC, et al. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. *Arch Pathol Lab Med* 2012;136(1):33–40.
23. Pont-Kingdon G, Gedge F, Wooderchak-Donahue W, et al. Design and analytical validation of clinical DNA sequencing assays. *Arch Pathol Lab Med* 2012;136(1):41–46.
24. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 1988;239(4839):487–491.
25. Mullis KB. The unusual origin of the polymerase chain reaction. *Sci Am* 1990;262(4):56–61, 64–65.
26. Bernard PS, Wittwer CT. Real-time PCR technology for cancer diagnostics. *Clin Chem* 2002;48(8):1178–1185.
27. Bench AJ, Baxter EJ, Green AR. Methods for detecting mutations in the human JAK2 gene. *Methods Mol Biol* 2013;967:115–131.
28. Halait H, Demartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. *Diagn Mol Pathol* 2012;21(1):1–8.
29. Furtado LV, Weigel HC, Elenitoba-Johnson KS, et al. Detection of MPL mutations by a novel allele-specific PCR-based strategy. *J Mol Diagn* 2013;15(6):810–818.
30. Lang AH, Drexel H, Geller-Rhomberg S, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. *J Mol Diagn* 2011;13(1):23–28.
31. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood* 2008;111(5):2505–2515.
32. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003;348(11):994–1004.
33. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2003;349(15):1423–1432.
34. Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. *J Mol Diagn* 2008;10(3):236–241.
35. Furtado LV, Weigel HC, Elenitoba-Johnson KS, et al. A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations. *J Mol Diagn* 2013;15(5):592–599.
36. Reed GH, Kent JO, Wittwer CT. High-resolution DNA melting analysis for simple and efficient molecular diagnostics. *Pharmacogenomics* 2007;8(6):597–608.
37. Palais RA, Liew MA, Wittwer CT. Quantitative heteroduplex analysis for single nucleotide polymorphism genotyping. *Anal Biochem* 2005;346(1):167–175.
38. Carillo S, Henry L, Lippert E, et al. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations—clinical relevance in the monitoring of polycythemia. *J Mol Diagn* 2011;13(3):263–270.
39. Ney JT, Froehner S, Roesler A, et al. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. *Arch Pathol Lab Med* 2012;136(9):983–992.
40. Jones AV, Cross NC, White HE, et al. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. *Haematologica* Oct 2008;93(10):1560–1564.
41. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 1977;74(12):5463–5467.
42. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. *Science* 1998;281(5375):363, 365.
43. Ronaghi M, Shokralla S, Charizadeh B. Pyrosequencing for discovery and analysis of DNA sequence variations. *Pharmacogenomics* 2007;8(10):1437–1441.
44. Shigaki H, Baba Y, Watanabe M, et al. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. *Ann Surg Oncol* 2013;20:485–491.
45. Vaughn CP, Zobell SD, Furtado LV, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. *Genes Chromosomes Cancer* 2011;50(5):307–312.
46. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. *Neuro Oncol* 2009;11(4):348–356.
47. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. *J Mol Diagn* 2007;9(3):368–381.
48. Dias-Santagata D, Akhavanfar S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2(5):146–158.
49. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. *J Mol Diagn* 2011;13(1):74–84.
50. Lazar A, Abruzzo LV, Pollock RE, et al. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. *Arch Pathol Lab Med* 2006;130(8):1199–1207.
51. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. *Nucleic Acids Res* 2005;33(14):e128.
52. Homig-Hölzel C, Savola S. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. *Diagn Mol Pathol* 2012;21(4):189–206.
53. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. *BMC Med* 2011;9:133.
54. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58(22):5248–5257.
55. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96(4):261–268.
56. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. *Clin Chem* 2009;55(4):641–658.
57. Cronin M, Ross JS. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. *Biomarker Med* 2011;5(3):293–305.
58. Coonrod EM, Durtschi JD, Margraf RL, et al. Developing genome and exome sequencing for candidate gene identification in inherited disorders: an integrated technical and bioinformatics approach. *Arch Pathol Lab Med* 2013;137(3):415–433.

59. Grossmann V, Kohlmann A, Klein HU, et al. Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure. *Leukemia* 2011;25(4):671–680.
60. Marchetti A, Del Grammasio M, Filice G, et al. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. *PLoS One* 2012;7(7):e42164.
61. McCourt CM, McArt DG, Mills K, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS One* 2013; 8(7):e69604.
62. Thol F, Kölling B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. *Genes Chromosomes Cancer* 2012;51(7):689–695.
63. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. *Cell* 2007;129(4):823–837.
64. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. *Nat Rev Genet* 2008;9(3):179–191.
65. Ren B, Robert F, Wyrick JJ, et al. Genome-wide location and function of DNA binding proteins. *Science* 2000;290(5500):2306–2309.
66. Robertson G, Hirst M, Bainbridge M, et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. *Nat Methods* 2007;4(8):651–657.
67. Shinawi M, Cheung SW. The array CGH and its clinical applications. *Drug Discov Today* 2008;13(17–18):760–770.
68. Iacobucci I, Lonetti A, Papayannidis C, Martinelli G. Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia. *Curr Cancer Drug Targets* 2013;13(7):791–810.
69. Ahmad A, Iqbal MA. Significance of genome-wide analysis of copy number alterations and UPD in myelodysplastic syndromes using combined CGH - SNP arrays. *Curr Med Chem* 2012;19(22):3739–3747.
70. Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. *J Natl Compr Canc Netw* 2013;11(2):174–182.